Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis

被引:0
|
作者
Silas, Ubong [1 ]
Blueher, Maximilian [1 ]
Smith, Antonia Bosworth [1 ]
Saunders, Rhodri [1 ]
机构
[1] Coreva Sci GmbH & Co KG, Konigswinter, Germany
来源
关键词
targeted therapy; turnaround time; health economic analysis; hospital costs; genetic testing; return on investment;
D O I
10.36469/jheor.2023.77686
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases. Molecular testing must be done to use targeted therapy. Unfortunately, the testing turnaround time can delay the initiation of targeted therapy. Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting. Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model. A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS. The model was from the perspective of a US hospital over a 5-year time horizon. All cost input data were in or inflated to 2021 USD. Scenario analysis was done on key variables. Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital. The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years. The payback period was 15 months with in-house NGS. The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used. Discussion: Reducing testing turnaround time is a benefit of in-house NGS. It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy. The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital. The model reflects a proposed scenario. The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed. Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy. Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 50 条
  • [21] Next generation sequencing: a prognostic and predictive factor in advanced and metastatic non-small cell lung cancer
    Deneft, Josephine
    Descamps, Olivier
    Nockerman, Helene
    Catala, Gaetan
    de Lovinfosse, Solange
    ACTA CLINICA BELGICA, 2023, 78 : 12 - 13
  • [22] Simultaneous Detection of Gene Rearrangements and Variants in Non-Small Cell Lung Cancer by Next-Generation Sequencing
    Xu, Shuo
    Boag, Alexander
    Mates, Mihaela
    Chen, Lina
    Feilotter, Harriet
    MODERN PATHOLOGY, 2016, 29 : 487A - 487A
  • [23] Next-Generation Sequencing of Liquid-Based Cytology Non-Small Cell Lung Cancer Samples
    Reynolds, Jordan P.
    Zhou, Yaolin
    Jakubowski, Maureen A.
    Wang, Zhen
    Brainard, Jennifer A.
    Klein, Roger D.
    Farver, Carol F.
    Almeida, Francisco A.
    Cheng, Yu-Wei
    CANCER CYTOPATHOLOGY, 2017, 125 (03) : 178 - 187
  • [24] Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing
    Kenmotsu, Hirotsugu
    Koh, Yasuhiro
    Serizawa, Masakuni
    Isaka, Mitsuhiro
    Maniwa, Tomohiro
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Nakajima, Takashi
    Ohde, Yasuhisa
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing
    Deeb, Kristin K.
    Hohman, Colleen M.
    Risch, Nicholas F.
    Metzger, Daniel J.
    Starostik, Petr
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (07) : 913 - 921
  • [26] Concordance of Next-Generation Sequencing Between Tissue and Liquid Biopsies in Non-Small Cell Lung Cancer
    Basher, F.
    Saravia, D.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S447 - S447
  • [27] Identification of Clinically Significant MUTYH Deletion by Next-Generation Sequencing in Non-Small Cell Lung Cancer
    Fong, A. H. W.
    Lau, E. Y. T.
    Cheung, W. K. C.
    Cho, W. C. S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S53 - S53
  • [28] Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing
    El Zaitouni, Sara
    Laraqui, Abdelilah
    Ghaouti, Meriem
    Benzekri, Asmae
    Kettani, Fouad
    Boustany, Youssra
    Benmokhtar, Soukaina
    Alaoui, Hafsa Lamrani
    El Annaz, Hicham
    Abi, Rachid
    Tagajdid, Mohamed Rida
    El Kochri, Safae
    El Mchichi, Bouchra
    Bouaiti, El Arbi
    Lahlou, Idriss Amine
    El Hassani, Rabii Ameziane
    Ennibi, Khalid
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [29] Simultaneous Detection of Gene Rearrangements and Variants in Non-Small Cell Lung Cancer by Next-Generation Sequencing
    Xu, Shuo
    Boag, Alexander
    Mates, Mihaela
    Chen, Lina
    Feilotter, Harriet
    LABORATORY INVESTIGATION, 2016, 96 : 487A - 487A
  • [30] Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
    Kratz, J.
    Harmon, G.
    Kosoff, D.
    Wubben, D.
    Laughlin, R.
    Traynor, A.
    Deming, D.
    Burkard, M.
    Leal, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S615 - S615